HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Social media ‘tears down walls’ in medicine
• Is social media a ‘slippery slope’ in medicine that should be avoided?
• Access to cancer clinical trials may not entirely level the playing field John Sweetenham, MD, FRCP, FACP
• Precision oncology: Exciting clinical developments and complicated biology Wafik S. El-Deiry, MD, PhD, FACP
• Poor air quality linked to hospitalizations among childhood cancer survivors
• Radiation improves outcomes with pembrolizumab for metastatic lung cancer
• Low PSA levels predict lack of benefit from long-term hormone therapy after prostate surgery
• Patients with lung cancer lack knowledge of clinical trials
• Plasma tumor mutational burden predicts outcomes with first-line pembrolizumab for metastatic NSCLC
• Researchers identify mutations associated with treatment sensitivity, resistance in NSCLC
• Association of Community Cancer Centers announces award recipients
• International Association for the Study of Lung Cancer announces president-elect, board members
• Cancer screening rates ‘unexpectedly high’ among adults aged 85 years and older
• High-volume, NCI-designated centers not associated with greater value in pancreatic cancer care
• Extended edoxaban, dalteparin equally effective among patients with cancer, venous thromboembolism
• Six prognostic factors identified for invasive breast cancer recurrence after DCIS
• FDA grants priority review to crizanlizumab for pain crises in sickle cell disease
• FDA approves Xpovio regimen for patients with relapsed or refractory multiple myeloma
• FDA grants fast track designation to CLR 131 for diffuse large B-cell lymphoma
• FDA grants breakthrough therapy designation to capmatinib for lung cancer subset
• $9 million grant funds trial of CAR T-cell therapy for metastatic breast cancer